LONG TERM IMPROVEMENT IN RENAL FUNCTION DURING CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE SUPPORT IS ASSOCIATED WITH USAGE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEIS) OR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS)  by Saeed, Omar et al.
Heart Failure and Cardiomyopathies
A889
JACC April 1, 2014
Volume 63, Issue 12
long terM iMproveMent in renal function during continuouS flow left ventricular 
aSSiSt device Support iS aSSociated with uSage of angiotenSin converting enzyMe 
inhibitorS (aceiS) or angiotenSin receptor blockerS (arbS)
Poster Contributions
Hall C
Sunday, March 30, 2014, 3:45 p.m.-4:30 p.m.
Session Title: Approaches to Advanced Heart Failure: From VAD, Transplant, Palliative Care to New Perctutaneous Therapies
Abstract Category: 12. Heart Failure and Cardiomyopathies: Clinical
Presentation Number: 1221-176
Authors: Omar Saeed, Rita Jermyn, Snehal Patel, Jooyoung Shin, David D’lessandro, Daniel Goldstein, Ronald Zolty, Montefiore Medical Center, 
Albert Einstein College of Medicine, Bronx, NY, USA
background: The effect of angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) on renal function during 
continuous flow left ventricular assist device support is unknown.
Methods: A retrospective analysis was conducted in all patients who underwent CF LVAD placement at our center from July 2006 to June 2013 
with a pre-implant GFR of <60 ml/min/1.73m2. Baseline demographics and changes in GFR at 1, 6 and 12 months after implantation were 
compared in patients who did and did not receive ACEIs or ARBs.
results: Thirty-two patients underwent CF LVAD placement with a baseline GFR of <60 ml/min/1.73m2. Eighteen of these patients received an 
ACEI or ARB, while the remaining 14 patients did not. Both groups had similar demographics, including mean age (ACEI/ARB: 59±11 vs. no ACEI/ARB: 
58±10 years; p= 0.81), diabetes mellitus and hypertension. In comparison to pre-implant renal function, the mean GFR of both groups improved 
after 1 month of CF LVAD support (ACEI/ARB: 44±4 to 65±5 ml/min/1.73m2, p<0.01; no ACEI/ARB: 36±4 to 48±4, p=0.02). Patients receiving 
an ACEI or ARB had sustained improvement in GFR at 12 months (74±8 ml/min/1.73m2, p<0.01) while those not on an ACEIs or ARBs showed no 
difference (44±4 ml/min/1.73m2, p=0.20) in comparison to pre-implant renal function.
conclusions: All patients showed an improvement in renal function after 1 month of CF LVAD support but sustained improvement was only 
observed in patients taking an ACEI or ARB.
